TREM2 Agonist Therapy for Parkinson's Disease — Experimental Design

SUMMARY

# TREM2 Agonist Therapy for Parkinson's Disease — Experimental Design ## Background and Rationale This experiment tests the TREM2-Alpha-Synuclein Clearance Hypothesis, investigating whether TREM2 agonism can enhance microglial phagocytosis of alpha-synuclein aggregates and provide neuroprotection in Parkinson's disease models. TREM2 (Triggering Receptor Expressed on Myeloid cells 2) is a critical microglial receptor that regulates phagocytosis, survival, and inflammatory responses. Recent eviden

METHODOLOGY NOTES

**Phase 1: Animal Preparation and Baseline Assessment (Weeks 1-2)** • Acquire 120 male C57BL/6J mice (8-10 weeks old, 25-30g) • Randomize into 4 groups (n=30 each): Control, PD model + vehicle, PD model + TREM2 agonist low dose (5mg/kg), PD model + TREM2 agonist high dose (15mg/kg) • Perform baseline behavioral assessments: rotarod test, cylinder test, and open field test • Collect baseline blood samples for biomarker analysis • Allow 7-day acclimatization period **Phase 2: Parkinson's Disease Model Induction (Week 3)** • Administer unilateral 6-OHDA lesion (8μg in 2μL saline + 0.02% ascorbic acid) into right medial forebrain bundle under stereotactic guidance • Control group receives saline injection at same coordinates • Monitor animals for 48h post-surgery with analgesics (buprenorphine 0.05mg/kg q12h) • Confirm lesion success at 2 weeks via amphetamine-induced rotation test (>7 rotations/min) **Phase 3: TREM2 Agonist Treatment (Weeks 5-12)** • Daily intraperitoneal injection of T